TWST vs. IOVA, NVAX, VIR, RLAY, ALLO, RGEN, PCVX, RVMD, EXEL, and HALO
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Iovance Biotherapeutics (IOVA), Novavax (NVAX), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), Allogene Therapeutics (ALLO), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), and Halozyme Therapeutics (HALO). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
Twist Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Iovance Biotherapeutics received 471 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.57% of users gave Iovance Biotherapeutics an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Twist Bioscience has higher revenue and earnings than Iovance Biotherapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Twist Bioscience presently has a consensus target price of $42.50, suggesting a potential upside of 1.43%. Iovance Biotherapeutics has a consensus target price of $24.64, suggesting a potential upside of 177.44%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Twist Bioscience.
Twist Bioscience has a net margin of -69.24% compared to Iovance Biotherapeutics' net margin of -23,615.70%. Twist Bioscience's return on equity of -31.61% beat Iovance Biotherapeutics' return on equity.
In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Twist Bioscience. MarketBeat recorded 10 mentions for Iovance Biotherapeutics and 5 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.14 beat Iovance Biotherapeutics' score of 0.59 indicating that Twist Bioscience is being referred to more favorably in the media.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by insiders. Comparatively, 10.4% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Iovance Biotherapeutics beats Twist Bioscience on 10 of the 17 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
